Synlogic (NASDAQ:SYBX – Get Free Report) and SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.
Profitability
This table compares Synlogic and SELLAS Life Sciences Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Synlogic | N/A | -26.47% | -18.00% |
| SELLAS Life Sciences Group | N/A | -95.20% | -75.06% |
Earnings and Valuation
This table compares Synlogic and SELLAS Life Sciences Group”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Synlogic | $8,000.00 | 861.70 | -$23.36 million | ($0.26) | -2.27 |
| SELLAS Life Sciences Group | N/A | N/A | -$30.88 million | ($0.28) | -20.79 |
Synlogic has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Synlogic has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500.
Institutional & Insider Ownership
63.4% of Synlogic shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 2.6% of Synlogic shares are held by insiders. Comparatively, 1.2% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Synlogic and SELLAS Life Sciences Group, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Synlogic | 1 | 0 | 0 | 0 | 1.00 |
| SELLAS Life Sciences Group | 1 | 0 | 1 | 0 | 2.00 |
SELLAS Life Sciences Group has a consensus price target of $7.00, suggesting a potential upside of 20.27%. Given SELLAS Life Sciences Group’s stronger consensus rating and higher probable upside, analysts clearly believe SELLAS Life Sciences Group is more favorable than Synlogic.
Summary
Synlogic beats SELLAS Life Sciences Group on 8 of the 12 factors compared between the two stocks.
About Synlogic
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.
